- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Microfluidics International Corporation (OTCBB: MFLU) today reported unaudited financial highlights for the first quarter ended March 31, 2009.
First Quarter Accomplishments
* Maintained revenues from the prior year's quarter despite global economic downturn
* Reduced corporate cost-structure during the quarter to 2007 levels under the direction of the new leadership team
"Microfluidics had a solid first quarter and we are pleased to report that we are beginning to see increased demand for our products and services in our core growth market—pharmaceuticals," said Michael C. Ferrara, Chief Executive Officer and President of Microfluidics. "The positive signs we saw in our first quarter revenues combined with our recent cost-containment measures have us on track to achieve our goal of obtaining positive EBITDA for the year 2009—a major milestone for the Company."
First Quarter Financial Results
Revenues for the three months ended March 31, 2009 were $3,559,000, an increase of $37,000, or 1.1%, as compared to revenues of $3,522,000 for the three months ended March 31, 2008. North American revenues increased by 64% and services revenues increased by approximately 50% in comparison to the first quarter of 2008, offsetting a 44.8% decline in foreign sales. The Company believes the decline in foreign sales is a result of pricing pressure in Asia Pacific and the effects of the global economic downturn.
Net loss, as measured under U.S. generally accepted accounting principles ("GAAP"), was $690,000, or $0.07 per diluted share, for the three months ended March 31, 2009 as compared to $445,000 net loss, or $0.04 per diluted share, for the same period in 2008.
EBITDA loss was $469,000, or $0.05 per diluted share, for the three months ended March 31, 2009 compared with a $410,000 EBITDA loss, or $0.04 per diluted share, for the same period in 2008.
Microfluidics International Corporation will host a webcast on Tuesday, May 12, 2009 at 8:30 a.m. Eastern Time. Participants are invited to attend the call by visiting www.mficcorp.com and clicking on the webcast link in the Investors, Events section or by dialing 800-638-4817 (within the United States) or 617-614-3943 (outside the United States). The passcode for participants is 25898820.
A replay will be available approximately two hours after the live call through May 19, 2009. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode for participants is 89775077. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of 30 days.
About Microfluidics International Corporation
Microfluidics International Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics and inkjet ink industries. Microfluidics International Corporation applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics International Corporation equipment customers.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture; our continued history of losses, which includes net losses in three of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including those regulating the exportation of goods; and general economic and business conditions and the financial crisis, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" of our most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this press release, whether as a result of new information, future events or otherwise.
EBITDA and Non-GAAP Measures
In addition to the results reported in accordance with generally accepted accounting standards (GAAP) within this release, the Company may reference certain information that is considered a non-GAAP financial measure. Management believes these measures are useful and relevant to management and investors in their analysis of the Company’s underlying business and operating performance. Management also uses this information for operational planning and decision-making purposes. Non-GAAP financial measures should not be considered a substitute for any GAAP measures. Additionally, non-GAAP measures as presented by the Company may not be comparable to similarly titled measures reported by other companies. One specific non-GAAP measure used by the Company is “EBITDA”, which is defined as earnings before interest, taxes, depreciation and amortization. Management utilizes the line item non-GAAP operations statement for operational planning and decision-making purposes. A reconciliation of GAAP to non-GAAP financial information discussed in this release is contained in the attached exhibits.
MICROFLUIDICS INTERNATIONAL CORPORATION Condensed Consolidated Balance Sheets (Unaudited - in thousands, except share and per share amounts) March 31, December 31, 2009 2008 ASSETS Current assets: Cash and cash equivalents $ 850 $ 1,895 Accounts receivable, net of allowance of $44 both at 2,536 2,181 March 31, 2009 and December 31, 2008, respectively Inventories 2,737 2,723 Prepaid and other current assets 220 320 Total current assets 6,343 7,119 Property and equipment, net 1,109 1,121 Other non-current assets 481 480 Total assets $ 7,933 $ 8,720 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,084 $ 986 Accrued expenses 1,151 1,233 Customer advances 280 436 Total current liabilities 2,515 2,655 Long-term liabilities: Convertible debt 4,638 4,625 Total liabilities 7,153 7,280 Stockholders' equity: Common stock; $.01 par value; 20,000,000 shares authorized; 10,607,228 and 10,592,228 shares issued; 10,371,782 and 106 106 10,356,782 shares outstanding as of March 31, 2009 and December 31, 2008, respectively Additional paid-in capital 18,072 18,042 Accumulated deficit (16,729 ) (16,039 ) Treasury stock, 235,446 shares, at cost, as of March 31, 2009 and (669 ) (669 ) December 31, 2008 Total stockholders' equity 780 1,440 Total liabilities and stockholders' equity $ 7,933 $ 8,720 MICROFLUIDICS INTERNATIONAL CORPORATION Condensed Consolidated Statements of Operations (Unaudited - in thousands, except share and per share amounts) For The Three Months Ended March 31, 2009 2008 Revenues $ 3,559 $ 3,522 Cost of sales 1,653 1,609 Gross profit 1,906 1,913 Operating expenses: Research and development 452 491 Selling 1,216 932 General and administrative 804 941 Total operating expenses 2,472 2,364 Loss from operations (566 ) (451 ) Interest expense (126 ) (5 ) Interest income 2 11 Net loss $ (690 ) $ (445 ) Net loss per common share: Basic $ (0.07 ) $ (0.04 ) Diluted $ (0.07 ) $ (0.04 ) Weighted average number of common and common equivalent shares outstanding: Basic 10,370,628 10,260,482 Diluted 10,370,628 10,260,482 MICROFLUIDICS INTERNATIONAL CORPORATION U.S. GAAP to Non-GAAP Measure Reconciliations and Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (Unaudited - in thousands, except share and per share amounts) For The Three Months Ended March 31, 2009 2008 Net loss $ (690 ) $ (445 ) Net interest expense (income) 125 (6 ) Depreciation and amortization 96 41 EBITDA (Non-GAAP Measure) $ (469 ) $ (410 ) Weighted average number of common and common equivalent shares outstanding: Basic: 10,370,628 10,260,482 Diluted: 10,370,628 10,260,482 EBITDA per common share (Non-GAAP Measure): Basic: $ (0.05 ) $ (0.04 ) Diluted: $ (0.05 ) $ (0.04 )
For more information, please click here
MacDougall Biomedical Communications
Sarah Cavanaugh, 781-235-3060
Microfluidics International Corporation
Peter F. Byczko, 617-969-5452
Vice President of Finance and Chief Accounting Officer
Copyright © Microfluidics International CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Testing Facility for Graphene Enhanced Composite Pipes May 5th, 2015
Light in a spin: Researchers demonstrate angular accelerating light April 15th, 2015
Device extracts rare tumor cells using sound: Microfluidic chip developed by CMU President Suresh and collaborators uses acoustic waves to separate circulating tumor cells from blood cells April 7th, 2015
Square ice filling for a graphene sandwich March 26th, 2015
Dolomite’s microfluidics technology ideal for B cell encapsulation March 24th, 2015
Testing Facility for Graphene Enhanced Composite Pipes May 5th, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
Heat-Converting Material Patents Licensed April 8th, 2015
FEI Company: Strong Growth Prospects Remain May 1st, 2015